Masimo Co. (NASDAQ:MASI – Get Free Report) has received an average rating of “Moderate Buy” from the seven research firms that are covering the company, Marketbeat reports. Three analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $144.67.
MASI has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Friday. Piper Sandler boosted their target price on Masimo from $160.00 to $165.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th.
Read Our Latest Research Report on MASI
Institutional Trading of Masimo
Masimo Stock Up 8.7 %
Shares of MASI opened at $121.42 on Monday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.15 and a current ratio of 2.09. Masimo has a 52 week low of $75.22 and a 52 week high of $153.93. The firm has a market capitalization of $6.46 billion, a price-to-earnings ratio of 82.60 and a beta of 0.98. The business’s fifty day moving average price is $115.01 and its two-hundred day moving average price is $124.98.
Masimo (NASDAQ:MASI – Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.09. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The company had revenue of $496.30 million for the quarter, compared to the consensus estimate of $493.92 million. During the same quarter in the prior year, the business posted $0.62 EPS. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. On average, analysts predict that Masimo will post 3.87 earnings per share for the current year.
About Masimo
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
Read More
- Five stocks we like better than Masimo
- Trading Halts Explained
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- 3 Best Fintech Stocks for a Portfolio Boost
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- 3 Small Caps With Big Return Potential
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.